Ruffer LLP
PFE icon

Ruffer LLP’s Pfizer PFE Stock Holding History

Ruffer LLP’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$18.3M Buy
1,128,755
+2,749
+0.2% +$73.1K 0.93% 34
2026
Q2 		$27.1M Sell
1,126,006
-23,747
-2% -$621K 0.96% 32
2026
Q1 		$32.4M Sell
1,149,753
-174,343
-13% -$4.64M 1.32% 21
2025
Q4 		$33M Sell
1,324,096
-698,969
-35% -$17.6M 1.5% 20
2025
Q3 		$51.5M Buy
2,023,065
+623,552
+45% +$15.4M 2.87% 11
2025
Q2 		$33.9M Sell
1,399,513
-792,785
-36% -$18.5M 1.5% 16
2025
Q1 		$55.6M Sell
2,192,298
-2,014,089
-48% -$52.7M 2.14% 10
2024
Q4 		$112M Sell
4,206,387
-2,319,901
-36% -$62.9M 4.03% 8
2024
Q3 		$189M Buy
6,526,288
+797,593
+14% +$23.3M 5.95% 6
2024
Q2 		$160M Sell
5,728,695
-178,963
-3% -$4.93M 6.88% 5
2024
Q1 		$164M Buy
5,907,658
+111,646
+2% +$3.1M 6.31% 4
2023
Q4 		$167M Buy
5,796,012
+4,133,786
+249% +$125M 6.2% 5
2023
Q3 		$53.3M Buy
1,662,226
+489,177
+42% +$17.3M 2.95% 12
2023
Q2 		$43M Buy
1,173,049
+101,370
+9% +$3.95M 2.52% 14
2023
Q1 		$43.7M Buy
1,071,679
+508,764
+90% +$22M 1.51% 24
2022
Q4 		$28.9M Buy
562,915
+8,140
+1% +$390K 1.94% 19
2022
Q3 		$23.9M Buy
554,775
+10,090
+2% +$490K 1.5% 22
2022
Q2 		$28.6M Sell
544,685
-33,949
-6% -$1.73M 1.13% 26
2022
Q1 		$30M Buy
578,634
+19,280
+3% +$1M 0.7% 33
2021
Q4 		$31.8M Buy
559,354
+124,464
+29% +$6.17M 0.77% 35
2021
Q3 		$18.6M Buy
434,890
+227,047
+109% +$10.1M 0.59% 30
2021
Q2 		$8.14M Buy
+207,843
New +$8.08M 0.23% 36
2015
Q2 		– Sell
-6,318
Closed -$209K – 101
2015
Q1 		$209K Buy
+6,318
New +$201K 0.01% 89
2014
Q3 		– Sell
-7,483
Closed -$213K – 89
2014
Q2 		$213K Hold
7,483
– – 0.01% 85
2014
Q1 		$228K Hold
7,483
– – 0.01% 89
2013
Q4 		$217K Hold
7,483
– – 0.01% 85
2013
Q3 		$206K Buy
+7,483
New +$204K 0.01% 84

Other funds holding PFE

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $54.1B AUM 39.29% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Ruffer LLP's PFE Position: Q3 2026 in Review

Ruffer LLP increased its Pfizer (PFE) stake by 0.24% in Q3 2026, buying an estimated $73.1K and bringing the position to 1,128,755 shares worth $18.3M. The position accounts for 0.93% of the portfolio, ranked #34.

Ruffer LLP first reported a position in PFE in Q3 2013 and has held it in 27 quarters since. The position peaked at $189M in Q3 2024. 2,002 funds tracked by Wall St. Rank hold PFE as of Q3 2026.

  • Ruffer LLP held 1,128,755 shares of Pfizer worth $18.3M as of Q3 2026.
  • Ruffer LLP bought 2,749 Pfizer shares in Q3 2026, an estimated $73.1K.
  • Pfizer made up 0.93% of Ruffer LLP's portfolio in Q3 2026, its #34 holding.
  • Ruffer LLP first reported a position in Pfizer in Q3 2013 and has held it in 27 quarters since.
  • Ruffer LLP's Pfizer position peaked at $189M in Q3 2024.
  • 2,002 funds tracked by Wall St. Rank held Pfizer as of Q3 2026.

Based on Ruffer LLP's 13F filing for Q3 2026, filed 10 Nov 2026.